Rosa M. Álvarez

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Edurne San José‐Eneriz, Xabier Agirre, Obdulia Rabal et al. · Nature Communications · 2017 · 161 citations · Full text

Hematological Malignancy, Reversible Chemical Probes, Epigenetic Drugs +15

Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α₂-Adrenoceptor Blocking Activity

José Ignacio Andrés, Jesús Alcázar, José Manuel Alonso Segura et al. · Journal of Medicinal Chemistry · 2004 · 49 citations · Full text

Psychopharmacology, Pharmacotherapy, New Series +16

Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors

Joaquı́n Pastor, Julen Oyarzábal, Gustavo Saluste et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 44 citations · Full text

Medicinal Chemistry, Medicine, Rational Drug Design +9

Novel Approach for Chemotype Hopping Based on Annotated Databases of Chemically Feasible Fragments and a Prospective Case Study: New Melanin Concentrating Hormone Antagonists

Julen Oyarzábal, Trevor Howe, Jesús Alcázar et al. · Journal of Medicinal Chemistry · 2009 · 32 citations · Full text

Combinatorial Chemistry, Drug Target, Bioorganic Chemistry +20

Imidazo[1,2-a]pyrazines as novel PI3K inhibitors

Sonia Martı́nez, Ana Isabel Hernández, Carmen Varela et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 31 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +7